January 31, 2014Heart
Release kinetics of early ischaemic biomarkers in a clinical model of acute myocardial infarction
Key result
Transcoronary ablation of septal hypertrophy significantly increased sFlt-1 and hFABP within 15 minutes compared to baseline (p<0.001), showing very early release kinetics.
Why the study?
What are the release kinetics of sFlt-1, IMA, and hFABP in a clinical model of acute myocardial infarction?
Population
21 consecutive patients with hypertrophic obstructive cardiomyopathy undergoing transcoronary ablation of…
Comparison
Transcoronary ablation of septal hypertrophy as… vs Baseline biomarker levels before TASH
Design
Cohort
Follow-up
24 hours
Authors
Discussion
Loading...
Member takes
Implication
May support ultra-early AMI biomarkers; leaves open validation in spontaneous infarction.
Study Design
Type
Observational (n=21)
Structured PICO
What are the release kinetics of sFlt-1, IMA, and hFABP in a clinical model of acute myocardial infarction?
P
Population
21 consecutive patients with hypertrophic obstructive cardiomyopathy undergoing transcoronary ablation of septal hypertrophy (TASH) followed for 24 hours.
E
Exposure
Transcoronary ablation of septal hypertrophy (TASH) as a clinical model of acute myocardial infarction
C
Comparator
Baseline biomarker levels before TASH
O
Outcome
Release kinetics of soluble fms-like tyrosine kinase (sFlt-1), ischaemia modified albumin (IMA), and heart-type fatty acid binding protein (hFABP) measured at multiple time points up to 24 hourssurrogate
Main Result
p-value: p=<0.001
sFlt-1 and hFABP increase as early as 15 minutes after induced myocardial ischemia, highlighting their potential as early biomarkers for acute myocardial infarction.
Cite This Study
Liebetrau et al. (2014) conducted an observational in Hypertrophic obstructive cardiomyopathy (n=21). Transcoronary ablation of septal hypertrophy (TASH) vs. Baseline was evaluated on Release kinetics of sFlt-1, IMA, and hFABP (p=<0.001). Transcoronary ablation of septal hypertrophy significantly increased sFlt-1 and hFABP within 15 minutes compared to baseline (p<0.001), showing very early release kinetics.